Possible scenario
Regulatory Friction Emerges
20% Chance
The deal attracts scrutiny from healthcare regulators, privacy officials, and research-integrity groups because OpenAI is moving deeper into regulated biomedical workflows. The most realistic constraint is not a blocked acquisition but tighter rules around clinical claims, patient data, and validation standards.
Secondary impacts
- Technology -0.4%
- Healthcare -0.2%
Tickers
- OBIO-5.3%
- MSFT-0.1%
Portfolio impact
S&P 500-0.2%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.